News|Articles|November 19, 2026

BELLWAVE Program for Nemtabrutinib Discontinued After Phase 3 CLL/SLL Trial

Fact checked by: Russ Conroy

An external data monitoring committee noted that nemtabrutinib’s benefits in first-line CLL/SLL may not outweigh its risks in the phase 3 BELLWAVE-011 trial.

Merck has discontinued the clinical development program evaluating nemtabrutinib (MK-1026), an investigational oral, non-covalent Bruton tyrosine kinase (BTK) inhibitor, in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other hematologic malignancies, the company announced.¹ The decision followed the discontinuation of the phase 3 BELLWAVE-011 trial (NCT06136559) after an external Data Monitoring Committee (eDMC) review suggested that the benefits of nemtabrutinib may not outweigh the risks in the study.

Why was the program for nemtabrutinib discontinued?

The discontinuation of the phase 3 BELLWAVE-011 trial followed the eDMC’s review of the results; the developers subsequently confirmed the committee’s assessment after reviewing the data in their totality. As a result of that analysis, Merck also decided to discontinue the broader BELLWAVE clinical development program, including the other phase 3 studies BELLWAVE-008 (NCT05624554) and BELLWAVE-010 (NCT05947851). The company stated that data analyses for these trials are ongoing and that the results will be shared with the scientific community. No efficacy or safety figures were disclosed in the announcement.

“Following careful analyses of the data from BELLWAVE-011, the decision has been made to discontinue development of nemtabrutinib across the entire clinical program. We are grateful to all of the patients, caregivers and investigators for their many contributions that made these studies possible,” said Marjorie Green, MD, senior vice president and head of global oncology clinical development at Merck Research Laboratories, in a news release.1 “We continue to pursue solutions for patients with hematologic malignancies and focus on advancing our hematology pipeline to help more patients with blood cancers.”

What were BELLWAVE-011 and nemtabrutinib?

BELLWAVE-011 was a phase 3 trial evaluating nemtabrutinib vs investigator’s choice of ibrutinib (Imbruvica) or acalabrutinib (Calquence) in patients with previously untreated CLL/SLL.2 The investigators hypothesized that nemtabrutinib was non-inferior vs ibrutinib or acalabrutinib in terms of eliciting objective responses as well as progression-free survival (PFS) based on blinded independent central review.

The trial’s primary end points were objective response rate and PFS per blinded independent central review. Secondary end points included overall survival, duration of response, and adverse effects.

Patients 18 years and older with a confirmed diagnosis of CLL/SLL, at least 1 marker of disease burden, and an ECOG performance status of 0 to 2 were eligible for enrollment on the trial. Those with gastrointestinal dysfunction that may affect drug absorption, Richter transformation or active central nervous system involvement by CLL/SLL, clinically significant cardiovascular disease, a history of severe bleeding disorder, or any prior systemic therapy for CLL/SLL were ineligible for study entry. Having receipt of prior radiotherapy within 2 weeks of beginning study intervention or a live-attenuated vaccine within 30 days of initiating treatment was also grounds for exclusion from the trial.

Nemtabrutinib is an investigational oral, non-covalent BTK inhibitor designed to suppress oncogenic B-cell receptor signaling. Unlike covalent BTK inhibitors such as ibrutinib and acalabrutinib, non-covalent inhibitors bind reversibly to BTK. In addition to BELLWAVE-011, nemtabrutinib had been evaluated across the BELLWAVE program, including the phase 3 BELLWAVE-008 and BELLWAVE-010 trials, as well as earlier studies such as BELLWAVE-001 (NCT03162536).

What comes next for patients and investigators?

Merck stated that it is informing study investigators for the affected clinical trials and is advising patients to speak with their study team and physician regarding next steps and treatment options. The company added that it remains focused on advancing its broader hematology pipeline.

References

  1. Merck announces update on BELLWAVE clinical development program evaluating nemtabrutinib. News release. Merck. November 17, 2026. Accessed November 19, 2026. https://tinyurl.com/2edbusb9
  2. A study of nemtabrutinib (MK-1026) versus comparator (investigator’s choice of ibrutinib or acalabrutinib) in first line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) (MK-1026-011/BELLWAVE-011). ClinicalTrials.gov. Updated November 17, 2026. Accessed November 19, 2026. https://tinyurl.com/3sx4hxuf

Related to this article